Related Experiment Video
Updated: Oct 7, 2026
Mouse Models Of Helicobacter Infection And Gastric Pathologies
Published on: October 18, 2018
Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils--a
1Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Background:
We previously demonstrated that Helicobacter pylori colonization evokes gastric mucosal inflammation and an extensive increase in lipid peroxides and glutathione in Mongolian gerbils. Zinc and its derivative, polaprezinc, have been reported to be potent antioxidants in gastric mucosa.
Aim:
To examine the effect of polaprezinc on gastric mucosal oxidative inflammation in H. pylori-colonized Mongolian gerbils.
Methods:
Sixty-eight male Mongolian gerbils were orally inoculated with H. pylori (ATCC43504, 5 x 10(8) CFUs/gerbil; H. pylori group) and 35 gerbils were inoculated with the culture media (control group). Twenty-two gerbils in the H. pylori and 13 gerbils in the control group were fed with diets containing polaprezinc (0.06%, 100 mg/kg, 10 times the usual clinical dose) (H. pylori + polaprezinc group, polaprezinc group). The remaining gerbils were fed a standard laboratory chow diet. Neutrophil infiltration, assessed histologically and by the activity of myeloperoxidase, the contents of CXC-chemokine (GRO/CINC-1-like protein) and the contents of thiobarbituric acid-reactive substances, was evaluated in each group 12 weeks after the inoculation. Separately, gastric mucosal leucocyte activation and capillary perfusion were also assessed using intravital microscopy 2, 4, 8 and 12 weeks after the inoculation.
Results:
In all H. pylori-inoculated animals, the bacterial infection persisted throughout the experimental period. Gastric mucosal lesion formation in the H. pylori group was significantly inhibited in the H. pylori + polaprezinc group. Elevated levels of myeloperoxidase activity, GRO/CINC-1 and thiobarbituric acid-reactive substances in the H. pylori group at 12 weeks were attenuated significantly by polaprezinc treatment. Enhanced levels of venular leucocyte activation observed in the H. pylori group were attenuated significantly in the H. pylori + polaprezinc group during both the early phase (2 weeks) and late phase (12 weeks).
Conclusion:
Polaprezinc inhibited H. pylori-associated gastric mucosal oxidative inflammation, including initial micro-vascular leucocyte activation, in Mongolian gerbils.
Insights
Polaprezinc effectively reduced Helicobacter pylori-induced gastric inflammation and oxidative stress in gerbils. This antioxidant treatment inhibited neutrophil infiltration and micro-vascular leukocyte activation, suggesting therapeutic potential.
Area of Science:
- Gastroenterology
- Microbiology
- Pharmacology
Background:
- Helicobacter pylori (H. pylori) infection causes gastric inflammation and oxidative stress.
- Polaprezinc, a zinc derivative, exhibits antioxidant properties in the gastric mucosa.
Purpose of the Study:
- To investigate the therapeutic effects of polaprezinc on H. pylori-associated gastric mucosal oxidative inflammation in Mongolian gerbils.
Main Methods:
- Mongolian gerbils were infected with H. pylori or control media, with some receiving polaprezinc treatment.
- Assessed neutrophil infiltration, myeloperoxidase activity, chemokine levels, and lipid peroxidation.
- Evaluated leukocyte activation and capillary perfusion using intravital microscopy.
Main Results:
- Polaprezinc significantly inhibited gastric mucosal lesion formation in H. pylori-infected gerbils.
- Treatment reduced elevated myeloperoxidase activity, chemokine levels, and lipid peroxidation markers.
- Polaprezinc attenuated leukocyte activation in gastric venules during early and late infection phases.
Conclusions:
- Polaprezinc demonstrates efficacy in inhibiting H. pylori-associated gastric mucosal oxidative inflammation.
- The compound reduces micro-vascular leukocyte activation, a key inflammatory marker.
Related Concept Videos
01:26Gastritis II: Pathophysiology
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:24Peptic Ulcer Disease II: Pathophysiology
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
01:27Peptic Ulcer